Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 2 Nov 2006 |
| Reijo Salonen appointed to Orion?s new Senior Vice President, Research and Development | 20 Oct 2006 |
| 51,100 Orion A-shares converted into B-shares | 20 Oct 2006 |
| Composition of the Nomination Committee of Orion Corporation | 16 Oct 2006 |
| Decisions by the shareholders? meeting of the demerged Orion | 16 Oct 2006 |